MMIRF
Price
$0.09
Change
+$0.04 (+80.00%)
Updated
Sep 16 closing price
Capitalization
42.78M
SLS
Price
$1.60
Change
+$0.05 (+3.21%)
Updated
Sep 30, 03:47 PM (EDT)
Capitalization
203.72M
43 days until earnings call
Interact to see
Advertisement

MMIRF vs SLS

Header iconMMIRF vs SLS Comparison
Open Charts MMIRF vs SLSBanner chart's image
Medmira
Price$0.09
Change+$0.04 (+80.00%)
Volume$500
Capitalization42.78M
SELLAS Life Sciences Group
Price$1.60
Change+$0.05 (+3.21%)
Volume$300
Capitalization203.72M
MMIRF vs SLS Comparison Chart in %
Loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MMIRF vs. SLS commentary
Sep 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMIRF is a Hold and SLS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 30, 2025
Stock price -- (MMIRF: $0.09 vs. SLS: $1.56)
Brand notoriety: MMIRF and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MMIRF: 9% vs. SLS: 159%
Market capitalization -- MMIRF: $42.78M vs. SLS: $203.72M
MMIRF [@Biotechnology] is valued at $42.78M. SLS’s [@Biotechnology] market capitalization is $203.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MMIRF’s FA Score shows that 0 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • MMIRF’s FA Score: 0 green, 5 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, MMIRF is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MMIRF’s TA Score shows that 4 TA indicator(s) are bullish while SLS’s TA Score has 3 bullish TA indicator(s).

  • MMIRF’s TA Score: 4 bullish, 4 bearish.
  • SLS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, MMIRF is a better buy in the short-term than SLS.

Price Growth

MMIRF (@Biotechnology) experienced а 0.00% price change this week, while SLS (@Biotechnology) price change was -9.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.56%. For the same industry, the average monthly price growth was +12.05%, and the average quarterly price growth was +67.95%.

Reported Earning Dates

SLS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+3.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLS($204M) has a higher market cap than MMIRF($42.8M). MMIRF YTD gains are higher at: 587.023 vs. SLS (50.000). MMIRF has higher annual earnings (EBITDA): -3.24M vs. SLS (-27.18M). SLS has more cash in the bank: 25.3M vs. MMIRF (18.3K). SLS has less debt than MMIRF: SLS (737K) vs MMIRF (10.2M). MMIRF has higher revenues than SLS: MMIRF (254K) vs SLS (0).
MMIRFSLSMMIRF / SLS
Capitalization42.8M204M21%
EBITDA-3.24M-27.18M12%
Gain YTD587.02350.0001,174%
P/E RatioN/AN/A-
Revenue254K0-
Total Cash18.3K25.3M0%
Total Debt10.2M737K1,384%
FUNDAMENTALS RATINGS
MMIRF vs SLS: Fundamental Ratings
MMIRF
SLS
OUTLOOK RATING
1..100
3263
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4061
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (35) in the null industry is in the same range as SLS (53) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SLS’s over the last 12 months.

MMIRF's Profit vs Risk Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SLS’s over the last 12 months.

SLS's SMR Rating (99) in the Biotechnology industry is in the same range as MMIRF (100) in the null industry. This means that SLS’s stock grew similarly to MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (40) in the null industry is in the same range as SLS (61) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SLS’s over the last 12 months.

MMIRF's P/E Growth Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that MMIRF’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MMIRFSLS
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AYURF0.03N/A
+17.65%
AYURCANN HLDGS CORP.
ASHTF68.081.59
+2.40%
Ashtead Group PLC
CSWYF1.00N/A
N/A
China Shineway Pharmaceutical Group Ltd.
ARKAY63.89-0.05
-0.08%
Arkema
MRTI57.25-4.75
-7.66%
Maxus Realty Trust, Inc.

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and NWPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and NWPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
NWPHF - MMIRF
30%
Poorly correlated
N/A
TECX - MMIRF
29%
Poorly correlated
+4.74%
AZTR - MMIRF
24%
Poorly correlated
+1.43%
SRPT - MMIRF
22%
Poorly correlated
+2.51%
SLS - MMIRF
21%
Poorly correlated
-4.29%
More